Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway

NCT05578092 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT05578092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05578092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 2, 2022
Completion date
February 3, 2026
Enrollment
64 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, colo-rectal cancer, non small cell lung cancer, solid tumor